JP2010531638A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010531638A5 JP2010531638A5 JP2010512360A JP2010512360A JP2010531638A5 JP 2010531638 A5 JP2010531638 A5 JP 2010531638A5 JP 2010512360 A JP2010512360 A JP 2010512360A JP 2010512360 A JP2010512360 A JP 2010512360A JP 2010531638 A5 JP2010531638 A5 JP 2010531638A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- protein
- caspase
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 412
- 108090000623 proteins and genes Proteins 0.000 claims description 230
- 230000014509 gene expression Effects 0.000 claims description 156
- 102000004169 proteins and genes Human genes 0.000 claims description 132
- 210000004248 oligodendroglia Anatomy 0.000 claims description 121
- 230000030833 cell death Effects 0.000 claims description 115
- 210000002569 neuron Anatomy 0.000 claims description 113
- 150000007523 nucleic acids Chemical class 0.000 claims description 85
- 230000001105 regulatory effect Effects 0.000 claims description 69
- 230000001939 inductive effect Effects 0.000 claims description 64
- 102000039446 nucleic acids Human genes 0.000 claims description 59
- 108020004707 nucleic acids Proteins 0.000 claims description 59
- 210000004498 neuroglial cell Anatomy 0.000 claims description 52
- 108090000566 Caspase-9 Proteins 0.000 claims description 50
- 102000004039 Caspase-9 Human genes 0.000 claims description 49
- 239000003446 ligand Substances 0.000 claims description 48
- 239000013598 vector Substances 0.000 claims description 45
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 claims description 40
- 210000001130 astrocyte Anatomy 0.000 claims description 35
- 210000004116 schwann cell Anatomy 0.000 claims description 29
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 27
- 108010033644 N-acylsphingosine galactosyltransferase Proteins 0.000 claims description 26
- 102000055325 Myelin P0 Human genes 0.000 claims description 24
- 108050003852 Myelin protein P0 Proteins 0.000 claims description 24
- 108010005298 Oligodendrocyte-Myelin Glycoprotein Proteins 0.000 claims description 24
- 102100026746 Oligodendrocyte-myelin glycoprotein Human genes 0.000 claims description 24
- 102100035917 Peripheral myelin protein 22 Human genes 0.000 claims description 24
- 101710199257 Peripheral myelin protein 22 Proteins 0.000 claims description 24
- 238000006471 dimerization reaction Methods 0.000 claims description 23
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 23
- 108010076667 Caspases Proteins 0.000 claims description 22
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims description 22
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 22
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 claims description 22
- 102000011727 Caspases Human genes 0.000 claims description 21
- 108020001507 fusion proteins Proteins 0.000 claims description 21
- 102000037865 fusion proteins Human genes 0.000 claims description 21
- 102100026376 Artemin Human genes 0.000 claims description 20
- 101710205806 Artemin Proteins 0.000 claims description 20
- 102100021584 Neurturin Human genes 0.000 claims description 19
- 108010015406 Neurturin Proteins 0.000 claims description 19
- 239000013603 viral vector Substances 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 18
- 230000034994 death Effects 0.000 claims description 16
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims description 15
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 claims description 15
- 239000004098 Tetracycline Substances 0.000 claims description 14
- 229960002180 tetracycline Drugs 0.000 claims description 14
- 229930101283 tetracycline Natural products 0.000 claims description 14
- 235000019364 tetracycline Nutrition 0.000 claims description 14
- 150000003522 tetracyclines Chemical class 0.000 claims description 14
- 108010010974 Proteolipids Proteins 0.000 claims description 13
- 102000016202 Proteolipids Human genes 0.000 claims description 13
- 101000933115 Mus musculus Caspase-4 Proteins 0.000 claims description 12
- 108010077641 Nogo Proteins Proteins 0.000 claims description 12
- 102100036660 Persephin Human genes 0.000 claims description 12
- 102100029831 Reticulon-4 Human genes 0.000 claims description 12
- 239000000411 inducer Substances 0.000 claims description 12
- 108010070453 persephin Proteins 0.000 claims description 12
- 210000000274 microglia Anatomy 0.000 claims description 11
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 10
- 108010036280 Aquaporin 4 Proteins 0.000 claims description 10
- 102000012002 Aquaporin 4 Human genes 0.000 claims description 10
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 10
- 229930105110 Cyclosporin A Natural products 0.000 claims description 10
- 108010036949 Cyclosporine Proteins 0.000 claims description 10
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 10
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims description 10
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 10
- 229960001265 ciclosporin Drugs 0.000 claims description 10
- 230000002025 microglial effect Effects 0.000 claims description 10
- 102000005962 receptors Human genes 0.000 claims description 10
- 108020003175 receptors Proteins 0.000 claims description 10
- 150000003431 steroids Chemical class 0.000 claims description 10
- 102000004068 Caspase-10 Human genes 0.000 claims description 9
- 108090000572 Caspase-10 Proteins 0.000 claims description 9
- 102000004046 Caspase-2 Human genes 0.000 claims description 9
- 108090000552 Caspase-2 Proteins 0.000 claims description 9
- 102000004091 Caspase-8 Human genes 0.000 claims description 9
- 108090000538 Caspase-8 Proteins 0.000 claims description 9
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims description 9
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims description 9
- 102100038916 Caspase-5 Human genes 0.000 claims description 8
- 101710090333 Caspase-5 Proteins 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 description 171
- 235000018102 proteins Nutrition 0.000 description 126
- 238000000034 method Methods 0.000 description 123
- 208000016192 Demyelinating disease Diseases 0.000 description 80
- 239000003795 chemical substances by application Substances 0.000 description 71
- 230000003902 lesion Effects 0.000 description 67
- 206010012305 Demyelination Diseases 0.000 description 64
- 230000006907 apoptotic process Effects 0.000 description 58
- 230000000694 effects Effects 0.000 description 56
- 241000700159 Rattus Species 0.000 description 54
- 241000700605 Viruses Species 0.000 description 54
- 210000003169 central nervous system Anatomy 0.000 description 52
- 201000006417 multiple sclerosis Diseases 0.000 description 46
- 210000001519 tissue Anatomy 0.000 description 45
- 230000009261 transgenic effect Effects 0.000 description 44
- 238000012360 testing method Methods 0.000 description 43
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 39
- 239000003550 marker Substances 0.000 description 39
- 210000000278 spinal cord Anatomy 0.000 description 39
- 230000001537 neural effect Effects 0.000 description 36
- 210000004556 brain Anatomy 0.000 description 34
- 230000003210 demyelinating effect Effects 0.000 description 34
- 230000001154 acute effect Effects 0.000 description 33
- 210000003050 axon Anatomy 0.000 description 32
- 230000006378 damage Effects 0.000 description 30
- 238000001727 in vivo Methods 0.000 description 30
- 230000004044 response Effects 0.000 description 30
- 102000006386 Myelin Proteins Human genes 0.000 description 26
- 108010083674 Myelin Proteins Proteins 0.000 description 26
- 210000005012 myelin Anatomy 0.000 description 26
- 208000027418 Wounds and injury Diseases 0.000 description 25
- 208000015181 infectious disease Diseases 0.000 description 25
- 208000014674 injury Diseases 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 238000000338 in vitro Methods 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 22
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 22
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 20
- 230000001054 cortical effect Effects 0.000 description 20
- 239000005090 green fluorescent protein Substances 0.000 description 20
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 108700019146 Transgenes Proteins 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 238000002347 injection Methods 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 102000040430 polynucleotide Human genes 0.000 description 19
- 108091033319 polynucleotide Proteins 0.000 description 19
- 239000002157 polynucleotide Substances 0.000 description 19
- 239000013543 active substance Substances 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 238000010186 staining Methods 0.000 description 18
- 230000006698 induction Effects 0.000 description 17
- 102000047918 Myelin Basic Human genes 0.000 description 16
- 230000008499 blood brain barrier function Effects 0.000 description 16
- 210000001218 blood-brain barrier Anatomy 0.000 description 16
- 238000001514 detection method Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 101710107068 Myelin basic protein Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 210000003205 muscle Anatomy 0.000 description 15
- 230000004770 neurodegeneration Effects 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 239000012867 bioactive agent Substances 0.000 description 14
- 230000023105 myelination Effects 0.000 description 14
- 230000008906 neuronal response Effects 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 238000002372 labelling Methods 0.000 description 13
- 210000002161 motor neuron Anatomy 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 241000713666 Lentivirus Species 0.000 description 12
- 238000010171 animal model Methods 0.000 description 12
- 230000001640 apoptogenic effect Effects 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 238000000799 fluorescence microscopy Methods 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- SPSGYTWOIGAABK-DQEYMECFSA-N [4-[(2s)-2-acetamido-3-[[(5s)-3-carbamoyl-2-(cyclohexylmethoxy)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-5-yl]amino]-3-oxopropyl]-2-phosphonophenyl]phosphonic acid Chemical compound C([C@H](NC(=O)C)C(=O)N[C@@H]1C2=CC(=C(OCC3CCCCC3)C=C2CCCC1)C(N)=O)C1=CC=C(P(O)(O)=O)C(P(O)(O)=O)=C1 SPSGYTWOIGAABK-DQEYMECFSA-N 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 230000003376 axonal effect Effects 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 238000003384 imaging method Methods 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 238000012423 maintenance Methods 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 10
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 10
- 208000012902 Nervous system disease Diseases 0.000 description 10
- -1 antibodies Substances 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 201000001119 neuropathy Diseases 0.000 description 10
- 230000007823 neuropathy Effects 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 210000003523 substantia nigra Anatomy 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 108010025020 Nerve Growth Factor Proteins 0.000 description 9
- 208000018737 Parkinson disease Diseases 0.000 description 9
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 9
- 230000002424 anti-apoptotic effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000003364 immunohistochemistry Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 208000033808 peripheral neuropathy Diseases 0.000 description 9
- 210000004786 perivascular cell Anatomy 0.000 description 9
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 8
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 8
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 8
- 206010003694 Atrophy Diseases 0.000 description 8
- 230000037444 atrophy Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 210000003007 myelin sheath Anatomy 0.000 description 8
- 210000003061 neural cell Anatomy 0.000 description 8
- 230000008439 repair process Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 7
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 7
- 238000000692 Student's t-test Methods 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 210000000653 nervous system Anatomy 0.000 description 7
- 210000000535 oligodendrocyte precursor cell Anatomy 0.000 description 7
- 210000001428 peripheral nervous system Anatomy 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 230000000861 pro-apoptotic effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000012353 t test Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 208000003098 Ganglion Cysts Diseases 0.000 description 6
- 208000025966 Neurological disease Diseases 0.000 description 6
- 108091008606 PDGF receptors Proteins 0.000 description 6
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 6
- 208000005400 Synovial Cyst Diseases 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000000877 corpus callosum Anatomy 0.000 description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 238000011532 immunohistochemical staining Methods 0.000 description 6
- 238000011503 in vivo imaging Methods 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 230000006576 neuronal survival Effects 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 5
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 5
- 102000015336 Nerve Growth Factor Human genes 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000004624 confocal microscopy Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000002518 glial effect Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000002055 immunohistochemical effect Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000003447 ipsilateral effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000010208 microarray analysis Methods 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 229940053128 nerve growth factor Drugs 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000002123 temporal effect Effects 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 210000000115 thoracic cavity Anatomy 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 4
- 239000004971 Cross linker Substances 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 4
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000001398 Granzyme Human genes 0.000 description 4
- 108060005986 Granzyme Proteins 0.000 description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 4
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 description 4
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 description 4
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000010256 biochemical assay Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000030570 cellular localization Effects 0.000 description 4
- 230000036755 cellular response Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000013425 morphometry Methods 0.000 description 4
- 230000000508 neurotrophic effect Effects 0.000 description 4
- 239000003900 neurotrophic factor Substances 0.000 description 4
- 238000006384 oligomerization reaction Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 210000000463 red nucleus Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 238000013042 tunel staining Methods 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 102100026882 Alpha-synuclein Human genes 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102000021350 Caspase recruitment domains Human genes 0.000 description 3
- 108091011189 Caspase recruitment domains Proteins 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 3
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 3
- 102000009058 Death Domain Receptors Human genes 0.000 description 3
- 108010049207 Death Domain Receptors Proteins 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000015212 Fas Ligand Protein Human genes 0.000 description 3
- 108010039471 Fas Ligand Protein Proteins 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 101000973177 Homo sapiens Nuclear factor interleukin-3-regulated protein Proteins 0.000 description 3
- 241000713333 Mouse mammary tumor virus Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 108090000742 Neurotrophin 3 Proteins 0.000 description 3
- 102100029268 Neurotrophin-3 Human genes 0.000 description 3
- 102100022163 Nuclear factor interleukin-3-regulated protein Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000711798 Rabies lyssavirus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000012288 TUNEL assay Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 210000003618 cortical neuron Anatomy 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000005064 dopaminergic neuron Anatomy 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 230000001744 histochemical effect Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000001259 mesencephalon Anatomy 0.000 description 3
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 3
- 229960000907 methylthioninium chloride Drugs 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 230000002474 noradrenergic effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000007084 physiological dysfunction Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000003594 spinal ganglia Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JBFQOLHAGBKPTP-NZATWWQASA-N (2s)-2-[[(2s)-4-carboxy-2-[[3-carboxy-2-[[(2s)-2,6-diaminohexanoyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)C(CC(O)=O)NC(=O)[C@@H](N)CCCCN JBFQOLHAGBKPTP-NZATWWQASA-N 0.000 description 2
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102100029855 Caspase-3 Human genes 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 2
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 2
- 101000849321 Homo sapiens Protein RRP5 homolog Proteins 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 241000714192 Human spumaretrovirus Species 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 2
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 108700028031 Myelin Basic Proteins 0.000 description 2
- OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 description 2
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100033976 Protein RRP5 homolog Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 2
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 230000005775 apoptotic pathway Effects 0.000 description 2
- 230000008335 axon cargo transport Effects 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 108010052621 fas Receptor Proteins 0.000 description 2
- 102000018823 fas Receptor Human genes 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000007387 gliosis Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960004184 ketamine hydrochloride Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 108010089256 lysyl-aspartyl-glutamyl-leucine Proteins 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 230000009223 neuronal apoptosis Effects 0.000 description 2
- 230000007514 neuronal growth Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000003238 somatosensory effect Effects 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000002739 subcortical effect Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- 101150106774 9 gene Proteins 0.000 description 1
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000011403 Alexander disease Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102000007272 Apoptosis Inducing Factor Human genes 0.000 description 1
- 108010033604 Apoptosis Inducing Factor Proteins 0.000 description 1
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 241001213911 Avian retroviruses Species 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000002029 Claudin Human genes 0.000 description 1
- 108050009302 Claudin Proteins 0.000 description 1
- 102100028736 Claudin-10 Human genes 0.000 description 1
- 102100039518 Claudin-12 Human genes 0.000 description 1
- 101710197000 Claudin-12 Proteins 0.000 description 1
- 102100039588 Claudin-15 Human genes 0.000 description 1
- 108090000997 Claudin-15 Proteins 0.000 description 1
- 102100040838 Claudin-19 Human genes 0.000 description 1
- 101710196827 Claudin-19 Proteins 0.000 description 1
- 102100038445 Claudin-2 Human genes 0.000 description 1
- 108090000580 Claudin-2 Proteins 0.000 description 1
- 102100038446 Claudin-5 Human genes 0.000 description 1
- 108090000582 Claudin-5 Proteins 0.000 description 1
- 102100038449 Claudin-6 Human genes 0.000 description 1
- 108090000229 Claudin-6 Proteins 0.000 description 1
- 102100026098 Claudin-7 Human genes 0.000 description 1
- 108050007296 Claudin-7 Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- DSRJIHMZAQEUJV-UHFFFAOYSA-N Cuprizon Chemical compound C1CCCCC1=NNC(=O)C(=O)NN=C1CCCCC1 DSRJIHMZAQEUJV-UHFFFAOYSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000035357 Focal Infection Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000713858 Harvey murine sarcoma virus Species 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 201000003398 IMAGe syndrome Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000027382 Mental deterioration Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 102000055324 Myelin Proteolipid Human genes 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 101710094913 Myelin proteolipid protein Proteins 0.000 description 1
- 241000713883 Myeloproliferative sarcoma virus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 108050003475 Neuregulin Proteins 0.000 description 1
- 102000014413 Neuregulin Human genes 0.000 description 1
- 102000048238 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108090000304 Occludin Proteins 0.000 description 1
- 102000003940 Occludin Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 101001018324 Rattus norvegicus Myelin basic protein Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 102000018779 Replication Protein C Human genes 0.000 description 1
- 108010027647 Replication Protein C Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000011131 Reticuloendothelial disease Diseases 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 102000005747 Transcription Factor RelA Human genes 0.000 description 1
- 108010031154 Transcription Factor RelA Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 101710087237 Whey acidic protein Proteins 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000004662 cellular morphological change Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 108090000999 claudin 10 Proteins 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009537 cortical lesion Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007946 glucose deprivation Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000008904 neural response Effects 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000007512 neuronal protection Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000028266 oligodendrocyte apoptotic process Effects 0.000 description 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000012673 purified plant extract Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000020129 regulation of cell death Effects 0.000 description 1
- 230000020284 regulation of myelination Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000020874 response to hypoxia Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 210000004092 somatosensory cortex Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000001161 time-correlated single photon counting Methods 0.000 description 1
- 238000001954 time-lapse fluorescence microscopy Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94344807P | 2007-06-12 | 2007-06-12 | |
| PCT/US2008/066774 WO2008154644A1 (en) | 2007-06-12 | 2008-06-12 | Targeted cell death |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013015116A Division JP2013081480A (ja) | 2007-06-12 | 2013-01-30 | 標的化された細胞死 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010531638A JP2010531638A (ja) | 2010-09-30 |
| JP2010531638A5 true JP2010531638A5 (enExample) | 2012-08-16 |
Family
ID=40130220
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010512360A Pending JP2010531638A (ja) | 2007-06-12 | 2008-06-12 | 標的化された細胞死 |
| JP2013015116A Pending JP2013081480A (ja) | 2007-06-12 | 2013-01-30 | 標的化された細胞死 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013015116A Pending JP2013081480A (ja) | 2007-06-12 | 2013-01-30 | 標的化された細胞死 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US8124749B2 (enExample) |
| EP (1) | EP2167688A4 (enExample) |
| JP (2) | JP2010531638A (enExample) |
| AU (1) | AU2008261644B2 (enExample) |
| CA (1) | CA2690815A1 (enExample) |
| IL (4) | IL202701A (enExample) |
| WO (1) | WO2008154644A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124749B2 (en) * | 2007-06-12 | 2012-02-28 | Case Western Reserve University | Targeted cell death |
| EP2473031A4 (en) * | 2009-09-02 | 2013-12-04 | Univ Chicago | METHOD AND SYSTEMS FOR THE INDUCIBLE ABERMENTATION OF NERVE CELLS |
| US8269827B2 (en) * | 2009-09-29 | 2012-09-18 | General Electric Company | System and methods for mapping fluorescent images into a bright field color space |
| WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| WO2013070079A2 (en) * | 2011-11-10 | 2013-05-16 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk, | miRNA IN BLOOD BRAIN BARRIER OF MS PATIENTS |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| CN105518018B (zh) * | 2013-03-15 | 2020-04-03 | 细胞基因公司 | 修饰的t淋巴细胞 |
| EP2978854A4 (en) | 2013-03-24 | 2017-01-11 | Oisin Biotechnologies | Systems and methods for the targeted production of a therapeutic protein within a target cell |
| RU2022105597A (ru) | 2016-11-14 | 2022-04-04 | Тулджен Инкорпорейтед | Искусственно созданная система управления функцией шк |
| CA3047140A1 (en) | 2017-01-09 | 2018-07-12 | Oisin Biotechnologies | Constructs for expression of therapeutic proteins in target cells |
| CN112312918A (zh) | 2018-04-18 | 2021-02-02 | 奥依信生物技术公司 | 促融合脂质纳米粒和制备其的方法以及其用于靶细胞特异性产生治疗蛋白和治疗与靶细胞有关的疾病、病况或障碍的用途 |
| CN115197989A (zh) * | 2021-04-09 | 2022-10-18 | 中国科学院分子细胞科学卓越创新中心 | 基于细胞死活表型的药物靶点拮抗剂的新型筛选系统 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US5071773A (en) * | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| US5175385A (en) * | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
| US6677311B1 (en) * | 1988-07-20 | 2004-01-13 | The Salk Institute For Biological Studies | Inducible HSV-TK in transformed cell populations |
| FR2637803B1 (fr) * | 1988-10-19 | 1993-07-09 | Ire Celltarg Sa | Ligands specifiques de recepteurs d'hormones steroides estrogenes et progestagenes, application et produits intermediaires de synthese |
| US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| WO1994029442A2 (en) * | 1993-06-14 | 1994-12-22 | Basf Aktiengesellschaft | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5464758A (en) * | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5589362A (en) * | 1993-06-14 | 1996-12-31 | Basf Aktiengesellschaft | Tetracycline regulated transcriptional modulators with altered DNA binding specificities |
| FR2717824B1 (fr) * | 1994-03-25 | 1996-04-26 | Rhone Poulenc Rorer Sa | Virus recombinants, préparation et utilisation en thérapie génique. |
| AU5103996A (en) * | 1995-03-09 | 1996-10-02 | Bavarian Nordic Research Institute A/S | Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy |
| US6143557A (en) * | 1995-06-07 | 2000-11-07 | Life Technologies, Inc. | Recombination cloning using engineered recombination sites |
| US5837837A (en) * | 1997-02-27 | 1998-11-17 | Millennium Pharmaceuticals, Inc. | Nucleic acids molecules encoding Caspase-8h and Caspase-8i |
| US6472520B2 (en) * | 1997-03-21 | 2002-10-29 | The Trustees Of Columbia University In The City Of New York | Rat PEG-3 promoter |
| US20030110524A1 (en) * | 1997-07-28 | 2003-06-12 | Bradley Michael John Stringer | Transgenic organisms and their uses |
| US6982082B1 (en) * | 1997-08-27 | 2006-01-03 | President And Fellows Of Harvard College | Gene therapy by cell specific targeting |
| US6984635B1 (en) * | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
| US6235872B1 (en) * | 1998-03-12 | 2001-05-22 | The Burnham Institute | Proapoptotic peptides dependence polypeptides and methods of use |
| US7033595B1 (en) * | 1998-08-04 | 2006-04-25 | Purdue Research Foundation | Pseudotyped retroviruses and stable cell lines for their production |
| JP5213202B2 (ja) * | 1998-10-28 | 2013-06-19 | バイシス・インコーポレーテツド | 細胞アレイならびに遺伝障害マーカーの検出および使用方法 |
| US6313373B1 (en) * | 1998-10-30 | 2001-11-06 | Case Western Reserve University | Tissue specific promoters and transgenic mouse for the screening of pharmaceuticals |
| US7109317B1 (en) | 1998-11-06 | 2006-09-19 | President And Fellows Of Harvard College | FK506-based regulation of biological events |
| US6903244B1 (en) * | 1999-02-26 | 2005-06-07 | University Of Utah Research Foundation | Mice which are +/− or −/− for the elastin gene as models for vascular disease |
| US6881555B2 (en) | 1999-03-19 | 2005-04-19 | Aventis Pharmaceuticals Inc. | AKT nucleic acids, polypeptides, and uses thereof |
| US6890726B1 (en) * | 1999-04-06 | 2005-05-10 | Oklahoma Medical Research Foundation | Method for selecting recombinase variants with altered specificity |
| JP2004500197A (ja) * | 2000-02-08 | 2004-01-08 | コーネル リサーチ ファンデーション インコーポレーテッド | 光ファイバーを通じた蛍光分光用の多光子励起 |
| US7196182B2 (en) * | 2000-05-24 | 2007-03-27 | The Burnham Institute | Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| US6781029B2 (en) * | 2000-07-13 | 2004-08-24 | University Of South Florida | Transgenic animal and methods |
| US6891081B1 (en) * | 2000-08-14 | 2005-05-10 | The Trustees Of Columbia University In The City Of New York | Transgenic mice over-expressing amyloid-beta alcohol dehydrogenase (ABAD) in brain as model of alzheimer's disease and uses thereof |
| US6753456B2 (en) * | 2000-09-07 | 2004-06-22 | California Institute Of Technology | Point mutant mice with hypersensitive alpha 4 nicotinic receptors: dopaminergic pathology and increased anxiety |
| US6967725B2 (en) * | 2000-10-13 | 2005-11-22 | Lucent Technologies Inc. | System and method for optical scanning |
| AU2002239538A1 (en) * | 2000-12-06 | 2002-06-18 | Deltagen, Inc. | Transgenic mice containing glucagon receptor gene disruptions |
| EP1360173A2 (en) * | 2001-01-25 | 2003-11-12 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| US7169564B1 (en) * | 2001-06-26 | 2007-01-30 | Anaderm Research Corporation | FKBP51/52 and CyP40-mediated mammalian hair growth |
| JP2005516732A (ja) * | 2002-02-14 | 2005-06-09 | ザ プロクター アンド ギャンブル カンパニー | 使い捨て排泄物収集器 |
| US7153685B2 (en) | 2002-03-11 | 2006-12-26 | The Board Of Trustees Of The University Of Illinois | Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells |
| US20060030541A1 (en) * | 2002-04-05 | 2006-02-09 | Proskelia | Genes involved in osteogenesis, and methods of use |
| US20060034767A1 (en) * | 2002-07-05 | 2006-02-16 | Roger Williams Medical Center | Targeting and tracking of cells to specific organs and tissues in vivo |
| US20050143330A1 (en) * | 2002-09-30 | 2005-06-30 | Ron Mandel | Method for the treatment of Parkinson's Disease |
| US7638331B2 (en) * | 2004-01-02 | 2009-12-29 | The Administration of the Tulane Rducation Fund | Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery |
| EP1711597B1 (en) * | 2004-01-14 | 2012-03-07 | Novahep AB | Human hepatic progenitor cells and methods of use thereof |
| US20060052327A1 (en) * | 2004-09-07 | 2006-03-09 | Lin Liu | Cell specific gene silencing using cell-specific promoters in vitro and in vivo |
| US20090010873A1 (en) * | 2004-11-29 | 2009-01-08 | Yeda Research And Development Co. Ltd. | Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis |
| EP1710316A1 (en) * | 2005-04-08 | 2006-10-11 | Max-Delbrück-Centrum Für Molekulare Medizin | Reconstructed human mariner transposon capable of stable gene transfer into chromosomes in vertebrates |
| US7423194B2 (en) * | 2005-06-14 | 2008-09-09 | University Of Chicago | Animal models for demyelination disorders |
| EP1909562A4 (en) * | 2005-06-14 | 2015-04-08 | Univ Chicago | METHOD FOR TREATING MYELIN LOSS STATES |
| US8124749B2 (en) * | 2007-06-12 | 2012-02-28 | Case Western Reserve University | Targeted cell death |
-
2008
- 2008-06-12 US US12/138,277 patent/US8124749B2/en not_active Expired - Fee Related
- 2008-06-12 CA CA2690815A patent/CA2690815A1/en not_active Abandoned
- 2008-06-12 AU AU2008261644A patent/AU2008261644B2/en not_active Ceased
- 2008-06-12 WO PCT/US2008/066774 patent/WO2008154644A1/en not_active Ceased
- 2008-06-12 US US12/664,387 patent/US20100299770A1/en not_active Abandoned
- 2008-06-12 EP EP08770889A patent/EP2167688A4/en not_active Withdrawn
- 2008-06-12 JP JP2010512360A patent/JP2010531638A/ja active Pending
-
2009
- 2009-12-13 IL IL202701A patent/IL202701A/en not_active IP Right Cessation
-
2011
- 2011-12-21 US US13/374,307 patent/US8704037B2/en not_active Expired - Fee Related
-
2012
- 2012-09-09 IL IL221853A patent/IL221853A0/en unknown
- 2012-09-09 IL IL221851A patent/IL221851A0/en unknown
- 2012-09-09 IL IL221852A patent/IL221852A0/en unknown
-
2013
- 2013-01-30 JP JP2013015116A patent/JP2013081480A/ja active Pending
- 2013-09-17 US US14/028,746 patent/US20140033334A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010531638A5 (enExample) | ||
| US8704037B2 (en) | Targeted cell death | |
| Mori et al. | Inducible gene deletion in astroglia and radial glia—a valuable tool for functional and lineage analysis | |
| JP7423206B2 (ja) | 新しいアルツハイマー病動物モデル | |
| JP2010509235A (ja) | 多発性硬化症の治療 | |
| Wu et al. | Multiple signaling factors and drugs alleviate neuronal death induced by expression of human and zebrafish tau proteins in vivo | |
| JPH10500564A (ja) | ニューロンプロモーターおよび利用 | |
| Liu et al. | Deletion of Calsyntenin-3, an atypical cadherin, suppresses inhibitory synapses but increases excitatory parallel-fiber synapses in cerebellum | |
| Reneker et al. | Lens-specific expression of PDGF-A in transgenic mice results in retinal astrocytic hamartomas. | |
| US20120233713A1 (en) | Methods and systems for inducible ablation of neural cells | |
| KR20240032021A (ko) | 신경 재프로그래밍을 위한 방법 및 조성물 | |
| US20080109914A1 (en) | Differential labeling of cells | |
| Titeux et al. | Differences in the activation of the GFAP gene promoter by prion and viral infections | |
| Schwarzer et al. | Reactivation of the neurogenic niche in the adult zebrafish statoacoustic ganglion following a mechanical lesion | |
| AU2014201772A1 (en) | Targeted cell death | |
| JP2009512853A (ja) | 動物個体の神経系の非侵襲的インビボ蛍光イメージング | |
| Davidsson et al. | Serotonergic Hyperinnervation in Non-Motor Circuits in the Parkinsonian Rat | |
| Autar et al. | ASNTR Abstracts 2019 | |
| WO2006050379A2 (en) | Modulation of serotonin neurons involving the pet-1 transcriptional control region | |
| Aboutalebi | Establishing and using the new Tet system to study Parkinson’s disease in mice | |
| Sharma | Efficacy of a novel neuronal death inhibitor in Alzheimer’s disease models | |
| Saunders | Circuit interactions between the cortex and basal ganglia | |
| Kim | Genetic investigation of Nogo and Nogo-66 receptor function: Focus on spinal cord injury |